Cedelizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Cedelizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD4
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
 ☒NcheckY (what is this?)  (verify)

Cedelizumab is a monoclonal antibody acting on the immune system.[1] Possible indications include the prevention of organ transplant rejections and the treatment of autoimmune diseases.[2]

It has been approved by both the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC).[3]

Vedolizumab is a humanized monoclonal antibody, which binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7) on T lymphocytes to interfere with lymphocyte trafficking to the gut.[3]

References[edit]

  1. ^ WHO Drug Information
  2. ^ The NDA pipeline. F-D-C Development Corporation. 2001.
  3. ^ a b Debnath P, Rathi PM (February 2021). "Vedolizumab in Inflammatory Bowel Disease: West versus East". Inflammatory Intestinal Diseases. 6 (1): 1–17. doi:10.1159/000512805. PMC 8015260. PMID 33850834.